Relay Therapeutics is a large accelerated filer with 220,959,470 shares of common stock outstanding as of October 30, 2026. The company remains a clinical-stage biopharmaceutical firm with no product revenue, incurring significant operating losses while focusing on the development of its precision medicine pipeline.
Relay Therapeutics reported third quarter 2026 financial results, highlighting a cash position of approximately $849 million. The company provided clinical updates for its breast cancer and vascular anomalies programs, including an expected enrollment completion for the Phase 3 ReDiscover-2 trial in mid-2027.
Term
Q3 2026
“This quarter, we are very pleased by the pace of enrollment of our ReDiscover-2 trial for second-line breast cancer and also look forward to sharing updated ReInspire data for vascular anomalies at ASH. In addition, we continue to prepare for our frontline breast cancer trial testing the selective-selective combination of zovegalisib and atirmociclib, and we were highly encouraged by the data we saw from Pfizer’s FourLight-1 trial, which we believe showed the potential advantage of a CDK4-selective approach.”
Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics
Relay Therapeutics Insider Peter Rahmer Sells $14K of Stock
Peter Rahmer sold 753 shares of Relay Therapeutics, Inc. at $18.62 a share, worth $14K in total on Oct 28, 2026. Shares held after the trade: 222,904 (-0.3%).
Relay Therapeutics President, R&D Donald A. Bergstrom Sells $41.9K of Stock
Donald A. Bergstrom, President, R&D, sold 2,252 shares of Relay Therapeutics, Inc. at $18.62 a share, worth $41.9K in total on Oct 28, 2026. Shares held after the trade: 396,878 (-0.6%).
Relay Therapeutics CFO Thomas Catinazzo Sells $27.4K of Stock
Thomas Catinazzo, CFO, sold 1,469 shares of Relay Therapeutics, Inc. at $18.62 a share, worth $27.4K in total on Oct 28, 2026. Shares held after the trade: 103,665 (-1.4%).
Relay Therapeutics President and CEO Sanjiv Patel Sells $872K of Stock
Sanjiv Patel, President and CEO, sold 48,199 shares of Relay Therapeutics, Inc. at $18.10 a share, worth $872K in total on Oct 7, 2026. Shares held after the trade: 471,301 (-9.3%).
Relay Therapeutics CFO Thomas Catinazzo Sells $325K of Stock
Thomas Catinazzo, CFO, sold 17,511 shares of Relay Therapeutics, Inc. at $18.58 a share, worth $325K in total on Oct 6, 2026. Shares held after the trade: 105,340 (-14.3%).